- Eli Lilly’s weight loss drug dramatically cuts risk of diabetes, company says The Hill
- Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight Investors | Eli Lilly and Company
- Mounjaro: the next big thing in weight loss, now heading to Israel The Jerusalem Post
- Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial CNBC
- Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says CNN
